Integrative modeling of drug therapy and the bone turnover.
Denosumab has been successfully used for the postmenopausal osteoporosis treatment. This research is focused on the computational analysis of the effect of denosumab on bone remodeling. Inspired by the advancement in the field of multiscale modeling , this research encompasses on the cellular and molecular bone remodeling key players. The model is designed to cover all the dominant interacting factors and their respective gradients. During this research, we have performed numerical experiments to validate our mathematical model, by interfacing it with the parametric values available in the literature. The novelty of our work relies in the fact that we have considered the effect of estrogen, sclerostin and NFATc1 during osteoporosis and their combined effect with the variable effect of denosumab during therapy. From our analysis, we have concluded that denosumab suppresses osteoclast differentiation, that results in reduced bone resorption. These results are in agreement with the experimental findings.